Perrigo completes generic Retin-A portfolio acquisition

DUBLIN — Perrigo announced Monday that it had completed its acquisition of  the Retin-A portfolio of generic products from Matawan Pharmaceuticals. From 2005 to 2013, Perrigo had been the distributor of all Retin-A generic products, which treat acne. 

 

“We are excited to complete this transaction; bringing a high barrier-to-entry, margin-enhancing product and greater reach to the extended topicals portfolio,” Perrio CEO Joseph Papa said. “This acquisition further strengthens Perrigo's strategic position as we continue our mission of providing Quality Affordable Healthcare Products to consumers around the world.”

 

Retin-A had generic and brand sales of $290 million in the 12 months ended November 2015.